Glucagon‐like peptide‐1 reduces hepatic glucose production indirectly through insulin and glucagon in humans
The DOI matches its Crossref record.
Abstract
The effect of glucagon‐like peptide‐1 (GLP‐1) on hepatic glucose production and peripheral glucose utilization was investigated with or without infusion of somatostatin to inhibit insulin and glucagon secretion in 13 healthy, non‐diabetic women aged 59 years. After 120 min 3‐3 H‐glucose infusion, GLP‐1 was added (4.5 pmol kg−1 bolus + 1.5 pmol kg−1 min−1). Without somatostatin (n = 6), GLP‐1 decreased plasma glucose (from 4.8 ± 0.2 to 4.2 ± 0.3 mmol L−1, P = 0.007). Insulin levels were increased (48 ± 3 vs. 243 ± 67 pmol L−1, P = 0.032), as was the insulin to glucagon ratio (P = 0.044). The rate of glucose appearance (Ra) was decreased (P = 0.003) and the metabolic clearance rate of glucose (MCR) was increased during the GLP‐1 infusion (P = 0.024 vs. saline). Also, the rate of glucose disappearance (Rd) was reduced during the GLP‐1 infusion (P = 0.004). Since Ra was reduced more than Rd, the net glucose flow was negative, which reduced plasma glucose. Somatostatin infusion (500 μ g h−1, n = 7) abolished the effects of GLP‐1 on plasma glucose, serum insulin, insulin to glucagon ratio, Ra, Rd, MCR and net glucose flow. The results suggest that GLP‐1 reduces plasma glucose levels mainly by reducing hepatic glucose production and increasing the metabolic clearance rate of glucose through indirectly increasing the insulin to glucagon ratio in healthy subjects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639
Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Self-citationThe Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Self-citationMechanisms of Recovery From Type 2 Diabetes After Malabsorptive Bariatric Surgery
Guidone, C., Manco, M., Valera-Mora, E., Iaconelli, A., Gniuli, D., Mari, A., Nanni, G., Castagneto, M., Calvani, M., & Mingrone, G. (2006) · Diabetes · doi:10.2337/db06-0068 · Cited by 368
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“Changes induced from GLP-1 or its analogs, in the liver, regulate a variety of processes including, hepatic gluconeogenesis, glycogen synthesis, and glycolysis (Figure 3) (1, 216, 217).”
Background
Metadata
- Authors
- LARSSON, H., HOLST, J. J., & AHRÉN, B.
- Venue
- Acta Physiologica Scandinavica
- Publisher
- Wiley
- Published
- 1997-07
- Volume
- 160
- Issue
- 4
- Pages
- 413-422
- ISSN
- 0001-6772 (ISSN-L)
- 1365-201X
- OpenAlex
- W2048998821
- Cited by
- 114
- References
- 0
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glucagon‐like peptide‐1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. https://app.cochat.ai/papers/10.1046/j.1365-201x.1997.00161.x
- The paper
- LARSSON, H., HOLST, J. J., & AHRÉN, B. (1997). Glucagon‐like peptide‐1 reduces hepatic glucose production indirectly through insulin and glucagon in humans. Acta Physiologica Scandinavica. https://doi.org/10.1046/j.1365-201x.1997.00161.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.